A Comparative Study between the Silver Based Drug Nano-Chitosan Complex and Abraxane

Biopharmaceutical research aims to develop new drug forms based on delivery systems to reduce adverse effects and prolonging the duration of the effect of the drug substance. Research on the long-term and short-term toxicological effects of the medication “Nano-chitosan complex of silver based on Schiff’s base†and the medication Abraxane administered repeatedly via the stomach. Toxicity was studied with orally administration for 14 days and chronic oral toxicity for 180 days, with experimental and control groups consisting of heterosexual mice. Live weight and hematological parameters were studied. Data analysis was performed using SPSS-22. Animals demonstrated locomotor activity comparable to control and no clinical signs of any disease. The difference in scores between the groups is not significant. Hematological parameters such as bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, total protein, glucose, and urea were studied. Results showed no significant differences between the groups and the Parameter of animals in the control group. Both drugs were classified as low-hazard substances. All groups of the tested animals received the researched preparations three times intragastrically, and none of these administrations had an adverse impact on the animals’ vital functions, confirming the lack of subchronic toxicity. The lack of chronic toxicity of the tested medications in all groups of animals was established by many drug injections administered over the course of the 180-day investigation. The medications at the tested levels have no cumulative toxic impact that would impair the kidneys’ and liver’s functioning status.